Willathgamuwa Nathalie Dilhara, Nammunige Manodya Kaushani, Thennakoon Thennakoon Mudiyanselage Hiranthika Piyumali, Nissanka Nissanka Mudiyanselage Tanuri Ayanga, Withanage Dona Manushi Dinasha, Rodrigo Nishadi Sachinthani, Logenthiran Prassana Varun
Coventry University, Coventry, UK.
Department of Anatomy, Uva Wellassa University, Badulla, Sri Lanka.
BMJ Open. 2024 Dec 31;14(12):e089058. doi: 10.1136/bmjopen-2024-089058.
Male infertility, defined as the inability to impregnate a fertile female, arises from various factors, among which sperm motility plays a pivotal role in determining reproductive potential. Seminal plasma, a complex fluid comprising diverse proteins, serves to nourish and support sperm, thereby facilitating their function within the female reproductive tract for successful conception. Normozoospermia denotes normal sperm motility in males, whereas asthenozoospermia indicates reduced sperm motility. This review seeks to assess the feasibility of augmenting sperm motility in men with asthenozoospermia through supplementation with seminal plasma or specific seminal plasma proteins.
A systematic literature review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines will be conducted. PubMed and Google Scholar databases will be systematically searched using predefined keywords and Boolean operators. The search strategy will encompass terms related to asthenozoospermia, normozoospermia, seminal plasma proteins, sperm motility and sperm movement. Additionally, reference lists of relevant articles will be scrutinised for additional studies. Inclusion criteria will encompass human studies published as original research articles between 2019 and 2023. Data extraction will be performed using a standardised form, encompassing author details, country of origin, publication year, study design, participant characteristics, outcomes and conclusions. The risk of bias within the selected studies will be evaluated using the Robvis visualisation tool.
Ethical approval is not required for this systematic review. The findings will be disseminated through publication in a peer-reviewed scientific journal and presentation at relevant conferences.
CRD42024526439.
男性不育被定义为无法使可育女性受孕，其由多种因素引起，其中精子活力在决定生殖潜能方面起着关键作用。精浆是一种包含多种蛋白质的复杂液体，用于滋养和支持精子，从而促进它们在女性生殖道内发挥功能以实现成功受孕。正常精子症表示男性精子活力正常，而弱精子症则表明精子活力降低。本综述旨在评估通过补充精浆或特定精浆蛋白来提高弱精子症男性精子活力的可行性。
将按照系统评价和Meta分析的首选报告项目（PRISMA）指南进行系统文献综述。将使用预定义的关键词和布尔运算符系统地搜索PubMed和谷歌学术数据库。搜索策略将涵盖与弱精子症、正常精子症、精浆蛋白、精子活力和精子运动相关的术语。此外，还将仔细检查相关文章的参考文献列表以寻找其他研究。纳入标准将包括2019年至2023年间作为原创研究文章发表的人体研究。将使用标准化表格进行数据提取，包括作者详细信息、原产国、出版年份、研究设计、参与者特征、结果和结论。将使用Robvis可视化工具评估所选研究中的偏倚风险。
本系统评价无需伦理批准。研究结果将通过在同行评审的科学期刊上发表以及在相关会议上展示来传播。
PROSPERO注册号：CRD42024526439。
